Seoul National University Hospital: Lymphoma trials

The registry lists 15 Lymphoma studies with Seoul National University Hospital as lead sponsor. 2 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 13Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific AntibodiesRecruitingNCT07014319Phase 2
• Venetoclax and Decitabine in R/R T-ALLRecruitingNCT06712121Phase 2
• Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasCompletedNCT02388490Phase 2Results posted
• Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT06941688Phase 2
• High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System LymphomaTerminatedNCT06625359Phase 2
• GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
• Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
• Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
• Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)TerminatedNCT03578198Phase 2
• Study of VTD in Waldenstrom's MacroglobulinemiaStatus unknownNCT03335098Phase 2
• Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell LymphomaCompletedNCT02840539Phase 2
• To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's LymphomaStatus unknownNCT02585947Phase 4
• Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid TumorCompletedNCT01212341Phase 1
• Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell LymphomaStatus unknownNCT01178658Phase 2
• Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell LymphomaStatus unknownNCT01178645Phase 2